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Abstract To formulate Functional Assessment of Cancer
Therapy-Meningioma (FACT-MNG), a web-based tumor
site-speciﬁc outcome instrument for assessing intracranial
meningioma patients following surgical resection or ste-
reotactic radiosurgery. We surveyed the relevant literature
available on intracranial meningioma surgery and sub-
sequent outcomes (38 papers), making note of which, if
any, QOL/outcome instruments were utilized. None of the
surgveyed papers included QOL assessment speciﬁc to
tumor site. We subsequently developed questions that were
relevant to the signs and symptoms that characterize each
of 11 intracranial meningioma sites, and incorporated them
into a modiﬁed combination of the Functional Assessment
of Cancer Therapy-Brain (FACT-BR) and SF36 outcome
instruments, thereby creating a new tumor site-speciﬁc
outcome instrument, FACT-MNG. With outcomes analysis
of surgical and radiosurgical treatments becoming more
important, measures of the adequacy and success of treat-
ment are needed. FACT-MNG represents a ﬁrst effort to
formalize such an instrument for meningioma patients.
Questions speciﬁc to tumor site will allow surgeons to
better assess speciﬁc quality of life issues not addressed in
the past by more general questionnaires.
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Introduction
OutcomesandQualityofLife (QOL) assessmentinstruments
are important for assessing the results of surgical and radio-
surgicaltreatment,aswellascomparingresultsacrossstudies
[16]. Many of these instruments assess QOL but not in a
manner that addresses the CNS symptoms/signs of speciﬁc
tumorsites.Thisbecomesincreasinglyrelevantwhendealing
withtumorsthattendtoarise inspeciﬁcintracraniallocations
which can lead to distinct symptom complexes with unique
effects on QOL that can be overlooked by less speciﬁc QOL
instruments. Recognizing these location-speciﬁc symptom
complexes allow us the opportunity to personalize the QOL
assessment towards distinct patient groups.
Meningiomas comprise one such class of location-spe-
ciﬁc intracranial tumors [31]. Accounting for some 20% of
intracranial tumors, they are generally histologically
benign and slow growing, but may become locally inva-
sive. Due to the risk of tumor growth and development of
focal neurological deﬁcits from mass effect, standard
treatment usually consists of surgical resection or stereo-
tactic radiosurgery.
QOL assessment provides information regarding efﬁ-
cacy of surgical/radiosurgical treatment and may serve as
an important decision-making tool for patients and physi-
cians who are weighing the risks and beneﬁts of brain
surgery, especially if their meningioma is of the benign
variety. While there are a variety of outcome assessment
tools currently available, they vary widely in terms of
scope (post-surgery QOL, post-cancer therapy QOL, post-
brain surgery QOL, etc.), and none are currently location-
speciﬁc. Currently, the instrument most accurately targeted
at assessing QOL following brain tumor resection is the
validated Functional Assessment of Cancer Therapy-Brain
(FACT-BR) [22, 23, 40].
The location-speciﬁc nature of clinical symptoms and
signs of intracranial meningiomas provides an opportunity
for an even more targeted QOL assessment; one that takes
into account site-speciﬁc symptoms [42]. This would
allow for a more detailed examination of an individual
patient’s QOL based on tumor site and pre/post-surgery
signs and symptoms. With these goals in mind, FACT-
MNG was created. An important part of developing such
an instrument was making it available freely in a web
based platform so that patients could access the ques-
tionnaire on regular set intervals without the need for
direct physician contact or instruction. The VisionTree
Optimal Care
TM (VTOC) secure web-based portal allows
for patients to enter the site through self-registration and
complete the FACT-MNG electronically. Upon registra-
tion, the patient automatically receives an email with their
secure login information providing ongoing access to the
survey. VTOC includes full reporting/tracking capabilities
to query the data which can be exported to Excel for
additional analysis.
Methods
Initial data was gathered by way of reviewing relevant
literature (via PubMed) which discussed and examined
intracranial meningioma surgical therapy as well as sub-
sequent outcomes. With 38 papers [1–15, 17–22, 24–30,
32–41] in hand meeting our search criteria, we reviewed
the assessment instruments utilized in each. While all of
the papers included outcomes, when it came to QOL
assessment, 2 of the 38 used SF36 [3, 19, 39] others used
FACT-BR [5, 22, 40], and 8 used a more basic patient
functionality-oriented Karnofsky Performance Status
(KPS) comparison [10, 13, 28, 32, 34, 36, 37], and less
than half (15 of 38 papers) utilized any QOL instrument
at all (FACT-BR, SF36, KPS Scale, or some other
instrument). None of the papers utilized site-speciﬁc
questions.
Table 1 SF-36 Questions incorporated into FACT-MNG
Not at all A little bit Somewhat Quite a bit Very much
I am limited in performing vigorous activities, such as running,
lifting heavy objects, participating in strenuous sports
01 2 3 4
I am limited in performing moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing golf
01 2 3 4
I have difﬁculty climbing several ﬂights of stairs 0 1 2 3 4
I have difﬁculty walking several blocks 0 1 2 3 4
I have difﬁculty bathing or dressing myself 0 1 2 3 4
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123Table 2 Site-speciﬁc questions
incorporated into FACT-MNG
Not
at all
A little
bit
Somewhat Quite
a bit
Very
much
Olfactory Groove Meningioma
My sense of smell is altered 0 1 2 3 4
My sense of taste is altered 0 1 2 3 4
My vision is altered 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
Tuberculum sellae meningioma
My vision is altered 0 1 2 3 4
Compared to before my surgery,
my vision is improved
01 2 34
My short term memory is worse 0 1 2 3 4
Optic nerve sheath meningioma
My vision is altered 0 1 2 3 4
Compared with prior to treatment,
my vision is improved
01 2 34
Sphenoid wing meningioma
My vision is altered 0 1 2 3 4
Compared with prior to treatment,
my vision is improved
01 2 34
I have numbness on my forehead 0 1 2 3 4
I have numbness on my cheek 0 1 2 3 4
I have double vision 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
Cavernous sinus meningioma
My vision is altered 0 1 2 3 4
I have double vision 0 1 2 3 4
I have numbness on my forehead 0 1 2 3 4
I have numbness on my cheek 0 1 2 3 4
I have numbness on my chin 0 1 2 3 4
Parasagittal/falx meningioma
My short term memory is worse 0 1 2 3 4
My leg is weak 0 1 2 3 4
My leg is numb 0 1 2 3 4
My arm is weak 0 1 2 3 4
My arm is numb 0 1 2 3 4
I have a blind spot in my vision 0 1 2 3 4
Tentorial meningioma
My vision is altered 0 1 2 3 4
I have double vision 0 1 2 3 4
I have numbness on my face 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
I have a blind spot in my vision 0 1 2 3 4
Petroclival meningioma
My vision is altered 0 1 2 3 4
I have double vision 0 1 2 3 4
I have numbness on my face 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
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To address the issue of site speciﬁcity, we created FACT-
MNG (Functional Assessment of Cancer Therapy-Menin-
gioma), an amalgamation of FACT-BR, SF36, and newly
formulated questions addressing tumor site-speciﬁc signs
and symptoms. Speciﬁcally, we started with FACT-BR as
our base and added questions from SF36 that were more
detailed in ascertaining the patient’s physical capabilities
(e.g., ability to perform light, mild, or strenuous activity
without difﬁculty) (Table 1). Our most signiﬁcant modiﬁ-
cation was the creation and inclusion of questions that were
relevant to the signs and symptoms that characterize one of
11 tumor sites: olfactory groove, tuberculum sella, optic
nerve sheath, sphenoid wing, cavernous sinus, parasagittal,
tentorium cerebelli, petroclival region, cerebellopontine
angle, cerebellar convexity, and foramen magnum
(Table 2, 3).
Following its creation, FACT-MNG was converted into
a web-based format (currently available for patients/phy-
sicians to download for free at https://www.optimal
care.com. In addition to the beneﬁts of offering FACT-
MNG digitally (streamlined data collection, storage, and
analysis), the dynamic delivery offered by a web-based
application allows patients to only answer questions per-
tinent to their tumor’s site. At UCSF we plan to introduce
patients to the web site and questionnaire with a small
business card containing the web site URL and suggested
time interval for assessment post-operatively at 3, 6, 12, 18,
24, 36, 48, 60, and 72 months. Any additional intervention
will re-start the assessment clock for the initial intervention
and begin a new follow-up session. The VTOC system can
be conﬁgured to release the FACT-MNG into the patient’s
portal at the speciﬁc time points noted above. An email
alert is automatically sent to remind the patient to login and
complete the survey at each time interval. The process is
Table 2 continued Not
at all
A little
bit
Somewhat Quite
a bit
Very
much
My hearing is worse than prior to treatment 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
Cerebellopontine angle (CPA) meningioma
I have numbness on my face 0 1 2 3 4
I have pain in my face 0 1 2 3 4
My hearing is worse than prior to treatment 0 1 2 3 4
I have ringing in my ear on the side of surgery 0 1 2 3 4
I have weakness of my face 0 1 2 3 4
I have problems with dizziness 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
Cerebellar convexity meningioma
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My arm is weak 0 1 2 3 4
My leg is weak 0 1 2 3 4
My arm is numb 0 1 2 3 4
My leg is numb 0 1 2 3 4
Foramen magnum meningioma
I have neck pain 0 1 2 3 4
My speech is slurred 0 1 2 3 4
I have trouble swallowing 0 1 2 3 4
My voice is hoarse 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My walking is worse than prior to treatment 0 1 2 3 4
I have shoulder pain 0 1 2 3 4
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Not
at all
A little
bit
Somewhat Quite
a bit
Very
much
Physical well-being
I have a lack of energy 0 1 2 3 4
I have nausea 0 1 2 3 4
Because of my physical condition, I have trouble meeting the needs of my family 0 1 2 3 4
I have pain 01 2 34
I am bothered by side effects of treatment 0 1 2 3 4
I feel ill 01 2 34
I am forced to spend time in bed 0 1 2 3 4
I am limited in performing vigorous activities, such as running, lifting heavy objects,
participaing in strenuous sports
01 2 34
I am limited in performing moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf
01 2 34
I have difﬁculty climbing several ﬂights of stairs 0 1 2 3 4
I have difﬁculty walking several blocks 0 1 2 3 4
I have difﬁculty bathing or dressing myself 0 1 2 3 4
Social/family well-being
I feel close to my friends 0 1 2 3 4
I get emotional support from my family 0 1 2 3 4
I get support from my friends 0 1 2 3 4
My family has accepted my illness 0 1 2 3 4
I am satisﬁed with family communication about my illness 0 1 2 3 4
I feel close to my partner (or the person who is my main support) 0 1 2 3 4
Regardless of your current level of sexual activity, please answer the following question.
If you prefer not to answer it, please check this box
Q
and go to the next section
I am satisﬁed with my sex life 0 1 2 3 4
Emotional well-being
I feel sad 01 2 34
I am satisﬁed with how I am coping with my illness 0 1 2 3 4
I am losing hope in the ﬁght against my illness 0 1 2 3 4
I feel nervous 0 1 2 3 4
I worry about dying 0 1 2 3 4
I worry that my condition will get worse 0 1 2 3 4
Functional well-being
I am able to work (include work at home) 0 1 2 3 4
My work (include work at home) is fulﬁlling 0 1 2 3 4
I am able to enjoy life 0 1 2 3 4
I have accepted my illness 0 1 2 3 4
I am sleeping well 0 1 2 3 4
I am enjoying things I usually do for fun 0 1 2 3 4
I am content with the quality of my life right now 0 1 2 3 4
Additional concerns
I am able to concentrate 0 1 2 3 4
I have had headaches 0 1 2 3 4
I have had seizure convulsions 0 1 2 3 4
I can remember new things 0 1 2 3 4
I get frustrated that I cannot do the things I used to 0 1 2 3 4
I am afraid of having a seizure (convulsion) 0 1 2 3 4
I have trouble with my eyesight 0 1 2 3 4
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Not
at all
A little
bit
Somewhat Quite
a bit
Very
much
I feel independent 0 1 2 3 4
I have trouble hearing 0 1 2 3 4
I am able to ﬁnd the right word(s) to say what I mean 0 1 2 3 4
I have difﬁculty expressing my thoughts 0 1 2 3 4
I am bothered by the change in my personality 0 1 2 3 4
I am able to make decisions and take responsibility 0 1 2 3 4
I am bothered by the drop in my contribution to the family 0 1 2 3 4
I am able to put my hands together 0 1 2 3 4
I need help caring for myself (bathing, dressing, eating, etc.) 0 1 2 3 4
I am able to my thoughts into action 0 1 2 3 4
I am able to read like I’m used to 0 1 2 3 4
I am able to write like I’m used to 0 1 2 3 4
I am able to drive a vehicle (my car, truck, etc.) 0 1 2 3 4
Tumor site-speciﬁc questions
Olfactory Groove Meningioma
My sense of smell is altered 0 1 2 3 4
My sense of taste is altered 0 1 2 3 4
My vision is altered 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
Tuberculum Sellae Meningioma
My vision is altered 0 1 2 3 4
Compared to before my surgery, my vision is improved 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
Optic Nerve Sheath Meningioma
My vision is altered 0 1 2 3 4
Compared with prior to treatment, my vision is improved 0 1 2 3 4
Sphenoid Wing Meningioma
My vision is altered 0 1 2 3 4
Compared with prior to treatment, my vision is improved 0 1 2 3 4
I have numbness on my forehead 0 1 2 3 4
I have numbness on my cheek
I have double vision 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
Cavernous Sinus Meningioma
My vision is altered 0 1 2 3 4
I have double vision 0 1 2 3 4
I have numbness on my forehead 0 1 2 3 4
I have numbness on my cheek 0 1 2 3 4
I have numbness on my chin 0 1 2 3 4
Parasagittal/Falx Meningioma
My short term memory is worse 0 1 2 3 4
My leg is weak 0 1 2 3 4
My leg is numb 0 1 2 3 4
My arm is weak 0 1 2 3 4
My arm is numb 0 1 2 3 4
I have a blind spot in my vision 0 1 2 3 4
Tentorial Meningioma
My vision is altered 0 1 2 3 4
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Not
at all
A little
bit
Somewhat Quite
a bit
Very
much
I have double vision 0 1 2 3 4
I have numbness on my face 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
I have a blind spot in my vision 0 1 2 3 4
Petroclival Meningioma
My vision is altered 0 1 2 3 4
I have double vision 0 1 2 3 4
I have numbness on my face 0 1 2 3 4
My short term memory is worse 0 1 2 3 4
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
My hearing is worse than prior to treatment 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
Cerebellopontine Angle (CPA) Meningioma
I have numbness on my face 0 1 2 3 4
I have pain in my face 0 1 2 3 4
My hearing is worse than prior to treatment 0 1 2 3 4
I have ringing in my ear on the side of surgery 0 1 2 3 4
I have weakness of my face 0 1 2 3 4
I have problems with dizziness 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
Cerebellar Convexity Meningioma
My coordination is affected 0 1 2 3 4
My arm is uncoordinated 0 1 2 3 4
My leg is uncoordinated 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My arm is weak 0 1 2 3 4
My leg is weak 0 1 2 3 4
My arm is numb 0 1 2 3 4
My leg is numb 0 1 2 3 4
Foramen Magnum Meningioma
I have neck pain 0 1 2 3 4
My speech is slurred 0 1 2 3 4
I have trouble swallowing 0 1 2 3 4
My voice is hoarse 0 1 2 3 4
My balance is worse than prior to treatment 0 1 2 3 4
My walking is worse than prior to treatment 0 1 2 3 4
I have shoulder pain 0 1 2 3 4
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123fully automated within VTOC using templates and calen-
dar reminders to ensure accuracy and compliance. A subset
of patients may not be proﬁcient with or have access to
computers, either due to educational differences, socio-
economic status, or as a result of their disease process and/
or treatment. For these selected patients, notiﬁcations by
mail can be utilized.
Conclusion
With QOL assessment becoming increasingly important as
an information, education and –outcomes assessment tool
for both physicians and patients, relying on an outcome
instrument too general in scope may leave more detailed,
but nonetheless pertinent, issues unexplored and unmea-
sured. While FACT-BR has been validated as an assess-
ment tool pertaining to brain tumors in general, those
tumors which associated with characteristic site-speciﬁc
signs and symptoms readily lend themselves towards QOL
assessment with an even further reﬁned scope. Intracranial
meningiomas offer one such opportunity and, on account of
their comprising almost one-ﬁfth of all intracranial tumors,
warrant the development of an outcome instrument with a
narrower scope.
This instrument is not yet clinically validated. Further
examination of FACT-MNG should revolve around quali-
fying its validity as compared to the outcome assessment
provided by other QOL instruments (most notably FACT-
BR) following meningioma surgical therapy. The authors
of this paper plan to investigate the use of this instrument in
a prospective fashion on their patient population and report
on the results at a future date.
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